Table 3.
Half-Lives of Potential Long-Acting Drugs
median terminal half-lives | ref | |
---|---|---|
rilpivirine (RPV) | 50 h | 302 |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202022s008lbledt.pdf | ||
tenofovir alafenamide (TAF) | 92 min* | *in dogs |
119 | ||
TFV-DP (active metabolite of TAF) | 50−180 h | 303,304 |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207561s002lbl.pdf | ||
islatravir (EFdA) | 78.5−128 h | 299 |